The Food and Drug Administration today announced it has revoked the emergency use authorizations for the Simoa Semi-Quantitative SARS-CoV-2 IgG Antibody Test and Simoa SARS-CoV-2 N Protein Antigen Test because no viable (non-expired) tests remain.
 

Related News Articles

Blog
This is a confusing time in the public health emergency. Americans are thinking less about COVID-19 on a daily basis and many are eager to move on. But COVID-…
Perspective
One important learning from the two-and-a-half-year COVID-19 pandemic is that the public health emergency (PHE) waivers made an enormous difference for…
Headline
Children infected with COVID-19 are at higher risk afterwards for certain symptoms or conditions, according to a study released today by the Centers for…
Headline
As directed by President Biden in April, the Department of Health and Human Services today released a national plan for researching the long-term effects…
Headline
Inpatient and outpatient prospective payment system hospitals, inpatient psychiatric facilities and PPS-exempt cancer hospitals have until Aug. 30 to preview…
Chairperson's File
Remaining resilient as new variants of COVID-19 spread. Launching mobile health services to help ensure equitable distribution of COVID-19 vaccines. Partnering…